BioCentury
ARTICLE | Clinical News

SomatoKine IGF-1/BP3: Phase II data

March 26, 2001 8:00 AM UTC

INSM updated previously reported open-label Phase II data showing that SomatoKine decreased daily insulin requirements and daily fasting glucose levels (see BioCentury, Dec. 4, 2000). In 12 patients r...